BL
BioLineRx Ltd.
BLRX · NASDAQ
$2.49 +1.10% (+$0.03)
1M -17.00%
Market Cap $10.8M
P/E Ratio -
Div. Yield -
ROE 47.11%
Bulios Fair Price
$3.22
29.5% upside
Current Price
$2.49
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BLRX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
54 /100
Fair P/S 7.74x
P/B 0.79x
P/E N/A
Growth
0 /100
Declining Book val. growth 29.00%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 69.82%
Net margin 574.26%
Op. margin 876.27%
Quality
0 /100
Poor ROIC 49.89%
ROE 47.11%
ROA 23.98%
Debt
47 /100
Moderate Debt/Equity 0.58x
Current ratio 1.20x
Int. coverage -8.22x
Stability
37 /100
Moderate Beta 0.70x
EPS volatility 121.11%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BLRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Philip A. Serlin
Employees
22
Headquarters
Hevel Modi'in
Upcoming events
23 NOV
Earnings
Upcoming earnings report